|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:triptorelin
|
|
gptkbp:activities
|
Gn RH agonist
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:1989
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:brand
|
gptkb:Trelstar
|
|
gptkbp:clinical_trial
|
Phase III
fertility preservation
hormonal therapy
hormone-sensitive cancers
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
hypersensitivity to triptorelin
|
|
gptkbp:developed_by
|
gptkb:Ipsen
|
|
gptkbp:dosage_form
|
powder for injection
once every 1 to 6 months
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Triptorelin Pamoate
|
|
gptkbp:ingredients
|
C64 H86 N18 O13 S
|
|
gptkbp:interacts_with
|
anticoagulants
antidiabetic medications
other Gn RH analogs
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_atype_of
|
L02 A E01
|
|
gptkbp:is_available_on
|
injectable solution
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
gptkb:endometriosis
precocious puberty
|
|
gptkbp:lifespan
|
3 hours
|
|
gptkbp:manager
|
intramuscular injection
|
|
gptkbp:marketed_as
|
gptkb:Ipsen
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:nutritional_value
|
high
|
|
gptkbp:previous_name
|
gptkb:battle
|
|
gptkbp:products
|
Goserelin
Leuprolide
|
|
gptkbp:research
|
reproductive health
oncology
endocrine disorders
pediatric endocrinology
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
fatigue
nausea
weight gain
hot flashes
decreased libido
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of
|
57773-63-4
|